RxDoctor Payments Data

Richard Clemons, MD

Internal Medicine · San Antonio, TXNPI 1740282664

Payments from drug & device makers

$12,250in general payments, 2019–2025

Across 784 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Daiichi Sankyo Inc.$897
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$12,231100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,250 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$177,570
Medicare patients
481
Services billed
4,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Soliqua 100-33Insulin Glargine/Lixisenatide63$63,652
JardianceEmpagliflozin42$54,057
EliquisApixaban40$47,872
MounjaroTirzepatide40$46,724
RybelsusSemaglutide24$43,870
OzempicSemaglutide34$43,294
XareltoRivaroxaban13$20,111
FarxigaDapagliflozin Propanediol12$19,187
TrulicityDulaglutide15$15,848
LinzessLinaclotide21$15,508
MyrbetriqMirabegron15$12,583
Tresiba Flextouch U-200Insulin Degludec13$9,982
Spiriva RespimatTiotropium Bromide16$8,257
Colesevelam Hcl24$7,546
Xigduo XrDapaglifloz Propaned/Metformin13$7,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,533$87,16358 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$41$63,65263 claims
Lilly USA, LLCMounjaro, Trulicity$1,111$62,57355 claims
Boehringer IngelheimJardiance, Spiriva Respimat$527$62,31458 claims
PfizerEliquis, Premarin, Paxlovid$544$58,84694 claims
Johnson & JohnsonXarelto, Invokana$310$25,72125 claims
AbbVieLinzess, Synthroid, Armour Thyroid$1,509$23,021105 claims
AstraZenecaFarxiga$1,131$19,18712 claims
Astellas Pharma US IncMyrbetriq$282$12,58315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →